Study of FYU-981 in Hyperuricemia With or Without Gout

NCT02344862 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

80

Enrollment

INDUSTRY

Sponsor class

Conditions

Hyperuricemia

Interventions

DRUG: FYU-981 High dose, (Oral daily dosing for 8 weeks)
DRUG: FYU-981 Middle dose, (Oral daily dosing for 8 weeks)
DRUG: FYU-981 Low dose, (Oral daily dosing for 8 weeks)
DRUG: Placebo, (Oral daily dosing for 8 weeks)

Sponsor

Fuji Yakuhin Co., Ltd.